Open AccessCell‐mediated immune response to human papillomavirus 16 E7 peptide pools in patients with cervical neoplasia
Author(s) -
LEE YONG SEOK,
LEE CHUNG WON,
SONG MIN JONG,
HO EUN MI,
KIM CHAN JOO,
PARK TAE CHUL,
KIM TAI GYU,
PARK JONG SUP
Publication year - 2011
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.1111/j.1600-0412.2011.01277.x
Subject(s) - medicine , elispot , immune system , cervical intraepithelial neoplasia , cervical cancer , immunology , hpv infection , human papillomavirus , virology , oncology , cancer , t cell
Objective . To identify characteristics of the cell‐mediated immune (CMI) response to human papillomavirus‐16 (HPV) E7 viral peptide pools to help the formulation of therapeutic vaccines. Design . Prospective study. Population . Korean women. Setting . University hospital. Methods . From December 2008 to August 2010, 33 HPV‐16‐positive patients, seven patients exhibiting a high‐risk HPV infection other than HPV‐16 with grade 2/3 cervical intraepithelial neoplasm (CIN2/3), and nine healthy control donors were enrolled. Main Outcome Measures . CMI response to synthetic HPV‐16 E7 overlapping peptide pools using the IFN‐γ ELISPOT assay. Results . The E7 sequence comprising amino acids 16–55 was a major immunogenic region. The CMI response to HPV‐16 E7 is highly type‐specific. The follow‐up CMI response may last longer than expected after the lesion is resected. Conclusions . We found that the E7 sequence comprising amino acids 16–55 is a major immunogenic region that is critical for the T‐cell‐mediated immune response with CIN2/3 or cervical cancer. The identification of CMI responses to HPV‐16 E7 peptide pools may provide insight into therapeutic vaccine trials for the control of HPV‐associated diseases.